Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,305 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07328516 | Natural History Study of Early Life Exposures in Agriculture (ELEA) | enrolling by invitation | — | 64,277 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00071045 | Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members | enrolling by invitation | — | 6,000 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 |
| clinicaltrials |
| NCT02473757 | Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | enrolling by invitation | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 25, 2026 | clinicaltrials |
| NCT06208878 | A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies | enrolling by invitation | — | 70 | CRISPR Therapeutics AGINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT03226704 | Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing | enrolling by invitation | — | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03628612 | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells | enrolling by invitation | Phase 2 | 500 | Autolus LimitedINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06987058 | RVU120 Rollover Study(ROVER-01) | enrolling by invitation | Phase 2 | 14 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT07168486 | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | enrolling by invitation | Phase 1 | 15 | University of Maryland, BaltimoreOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07103863 | Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis(AL-CA) | enrolling by invitation | — | 49 | Beijing Anzhen HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07813390 | Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure(HLA-AML) | enrolling by invitation | Phase 2 | 73 | Guangdong Second Provincial General HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06767891 | Real-world Study of Acalabrutinib(RESA) | enrolling by invitation | — | 160 | Ruijin HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07784309 | A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies | enrolling by invitation | Phase 1 | 13 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT01728402 | Pathogenesis of Hematologic Malignancies | enrolling by invitation | — | 5,000 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06472830 | MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study(MAGIC) | enrolling by invitation | — | 1,000 | Mayo ClinicOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06795126 | Little NIRVANA for Pediatric Pain and Anxiety | enrolling by invitation | N/A | 130 | Nationwide Children's HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05600933 | Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment | enrolling by invitation | — | 1,200 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03689595 | Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) | enrolling by invitation | — | 30,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05669989 | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | enrolling by invitation | Phase 2 | 70 | SanofiINDUSTRY | 17 | Jul 31, 2026 | clinicaltrials |
| NCT05673551 | VR-PAT During Home Burn Dressings - Multisite | enrolling by invitation | N/A | 220 | Nationwide Children's HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | enrolling by invitation | Phase 2 | 332 | Taiho Oncology, Inc.INDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT06767475 | Mindfulness-Based Stress Reduction to Improve Well-being in Black Adult Cancer Survivors, Community Faith-based Mindfulness Ministry(ComFaMM) | enrolling by invitation | N/A | 65 | Mayo ClinicOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT00923442 | Biology Studies of Hematologic Cancers | enrolling by invitation | — | 550 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02315599 | Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials | enrolling by invitation | — | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04996706 | Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study(LEO) | enrolling by invitation | — | 21,000 | Mayo ClinicOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07690761 | Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant(Rituximab+ Zan) | enrolling by invitation | Phase 2 | 12 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07499128 | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event | enrolling by invitation | N/A | 136 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07307833 | Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience | enrolling by invitation | — | 50 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651163 | Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 450 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651176 | Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 267 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06985576 | Long-term Study to Evaluate Safety and Persistence of GF-CART01 | enrolling by invitation | — | 18 | GenomeFrontier Therapeutics TW Co., Ltd.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06967467 | Allergy Delabeling in Antibiotic Stewardship - Evaluations(RENEW-EVAL) | enrolling by invitation | — | 80 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07587411 | Stepped-Care Support for Children With Leukaemia(STEP-Leukemia) | enrolling by invitation | N/A | 96 | Zhengzhou UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07563335 | Stage-Matched Psychosocial Intervention for Parent Caregivers of Children With Leukemia in Pakistan(SMP-CLP) | enrolling by invitation | N/A | 88 | Zhengzhou UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06665490 | Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash | enrolling by invitation | — | 15 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07172191 | Fecal Microbiota Transplantation Among Adult Patients With Hematological Malignancies(HEMAT-FMT) | enrolling by invitation | N/A | 100 | Del-Pest Central Hospital - National Institute of Hematology and Infectious DiseasesOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07215039 | Improving Prison Health Equity Through Cancer Literacy and Screening Awareness in Florida | enrolling by invitation | — | 1,200 | Mayo ClinicOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537257 | VEN+IDAC vs IDAC in AML | enrolling by invitation | Phase 2 / Phase 3 | 232 | Guangdong Second Provincial General HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07225920 | Understanding Needs of Older Patients Prior to Starting Cancer Treatment(PGA) | enrolling by invitation | N/A | 216 | Wake Forest University Health SciencesOTHER | 2 | Apr 8, 2026 | clinicaltrials |
| NCT07517510 | HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).(HVA-MPAL) | enrolling by invitation | Phase 2 | 40 | Guangdong Second Provincial General HospitalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07515430 | The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia | enrolling by invitation | — | 138 | Sun Yat-sen UniversityOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06211413 | Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors(SENTINEL) | enrolling by invitation | — | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07474051 | Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials(PERSIST) | enrolling by invitation | — | 178 | AvenCell Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05332054 | Long-Term Follow-up Study(LTFS) | enrolling by invitation | — | 150 | Caribou Biosciences, Inc.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07410403 | AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities(AI) | enrolling by invitation | — | 10 | Fuling ZhouOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07383298 | Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase | enrolling by invitation | — | 100 | Qian JiangOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07348575 | A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma | enrolling by invitation | Phase 3 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT00186147 | Bone Marrow Grafting for Leukemia and Lymphoma | enrolling by invitation | — | 9,999 | Stanford UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07258680 | BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas(BrEto-TCL) | enrolling by invitation | Phase 3 | 114 | N.N. Petrov National Medical Research Center of OncologyOTHER | 0 | Dec 2, 2025 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials